Frontiers in Immunology最新文献

{"title":"OligoDOM^TM: a T-cell response-enhancing platform applied to cancer immunotherapy.","authors":"Judith Del Campo, Séverine Valsesia, Elsa Nikly, Roberto Ruiu, Antonella Iacoviello, Elena Quaglino, Federica Cavallo, Dalil Hannani, Emilie Boucher, Florence Nicolas, Alexandre Le Vert, Francesco Doro","doi":"10.3389/fimmu.2025.1549112","DOIUrl":"10.3389/fimmu.2025.1549112","url":null,"abstract":"<p><strong>Background: </strong>Neoepitopes derived (0) from tumors are attractive cancer immunotherapy targets, especially when combined with immune checkpoint inhibitors (CPIs). Vaccines using lipid nanoparticle (LNP)-encapsulated mRNA to deliver neoepitopes have shown encouraging results in patients and animal models, due to T cell-dependent responses. However, a low mutational burden is often a predictor of poor CPI response: the immune response against the few available mutations can be insufficient. An enhanced response to these few mutations could increase CPI efficacy. Here, we investigate the potential of oligoDOM™, a self-assembling sequence, to improve neoepitope immunogenicity and antitumor efficacy in murine cancer models.</p><p><strong>Methods: </strong>LNP-formulated mRNA constructs encoding short epitope strings fused with oligoDOM™ were tested. Immune responses in mice were compared between constructs with oligoDOM™ and their controls. Specific T-cell responses against four tumor models (MC38, CT26, TC-1, B16-OVA) were measured using ELISpot in naïve mice. Two models (TC-1 and B16-OVA) were further selected for tumor growth efficacy testing.</p><p><strong>Results: </strong>LNP-formulated neoepitope-oligoDOM™ mRNA constructs induced a significantly superior immune response as compared with the control groups in four neoantigens tested. This increased specific immunogenicity is linked to antitumor growth effects in murine syngeneic cancer models such as the B16-OVA and TC-1. The induced T-cell immune response significantly correlated with tumor growth rate reduction.</p><p><strong>Discussion: </strong>Combining oligoDOM™ and LNP-mRNA technologies offers a versatile platform that allows for efficient short neoepitope strings delivery. This approach represents a feasible, potentially effective strategy for personalized cancer immunotherapy.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1549112"},"PeriodicalIF":5.7,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951937/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of the clinical and laboratory characteristics of neuromyelitis optica spectrum disorder with or without cerebrospinal fluid oligoclonal bands: a cohort with 36-month follow-up.","authors":"Wenbo Yang, Xiaoni Liu, Jie Wei, Hai Yu, Wanqing Wu, Jingguo Wang, Bo Deng, Xiaoqin Wu, Xiangjun Chen, Xiang Zhang","doi":"10.3389/fimmu.2025.1536853","DOIUrl":"10.3389/fimmu.2025.1536853","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to explore the significance of cerebrospinal fluid (CSF) oligoclonal bands (OCBs) in the clinical diagnosis and evaluation of neuromyelitis optica spectrum disorder (NMOSD).</p><p><strong>Methods: </strong>The demographic and clinical data of 143 aquaporin-4 immunoglobulin G (AQP4-IgG)-positive NMOSD patients were collected and analyzed, including the gender, age, clinical symptoms and signs, status of CSF OCBs, location and length of the affected spinal cord vertebral segments, Expanded Disability Status Scale (EDSS) at the first attack and at 36-month follow-up, relapse times within 36 months, concomitant connective tissue disease (CTD), and status of other autoimmune antibodies (oAIA).</p><p><strong>Results: </strong>There were 15 patients (10.5%) who were positive for OCBs (OCBs+). In contrast to those with negative OCBs (OCBs-), more OCBs+ cases had concomitant CTD [5/15 (33.3%) <i>vs</i>. 11/128 (8.6%), <i>p</i> = 0.014] and oAIA [9/15 (60.0%) <i>vs</i>. 37/128 (28.9%), <i>p</i> = 0.020]. OCBs+ patients had higher CSF cell counts [15.0 (27.0)/mm³ <i>vs</i>. 5.0 (12.0)/mm³, <i>p</i> = 0.008], higher IgG index [0.68 (0.23) <i>vs</i>. 0.52 (0.15), <i>p</i> < 0.001], and more relapses within 36 months [2.0 (3.0) <i>vs</i>. 1.0 (2.0), <i>p</i> = 0.039] than OCBs- patients. More OCBs+ patients had polynuclear cell predominance in the CSF than OCBs- patients (<i>p</i> = 0.032). There were no significant differences between the OCBs+ and the OCBs- patients in the distribution of lesion locations; the length of the affected spinal cord vertebral segments; the concentration of CSF protein and the albumin quotient; the EDSS score at the time of lumbar puncture and at 36-month follow-up, and the onset episode, the relapse, and cumulative clinical syndrome profiles (all <i>p</i> > 0.05).</p><p><strong>Conclusions: </strong>For AQP4-IgG-positive NMOSD patients, positivity for CSF OCBs is associated with higher CSF cell counts and a higher likelihood to have concomitant CTD and oAIA. OCBs+ is not uncommon in NMOSD and may predict more frequent relapses, but not a more serious illness.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1536853"},"PeriodicalIF":5.7,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11949817/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of the mRNA COVID-19 vaccine on the Th-like cytokine profile in individuals with no history of COVID-19: insights into autoimmunity targeting heat shock proteins.","authors":"Stefan Tukaj, Magdalena Sitna, Krzysztof Sitko","doi":"10.3389/fimmu.2025.1549739","DOIUrl":"10.3389/fimmu.2025.1549739","url":null,"abstract":"<p><p>Although some reports suggest that COVID-19 vaccination may exacerbate existing autoimmune diseases or trigger new-onset cases, a definitive causal relationship between the vaccines and these conditions has not been established. Several potential mechanisms have been proposed to explain this association, including: (i) molecular mimicry, which refers to a structural similarity between SARS-CoV-2 and human antigens; (ii) bystander activation, involving both B and T lymphocytes; and (iii) the effects of adjuvants. In this study, we investigated whether two doses of the mRNA COVID-19 vaccine influenced blood cytokine levels associated with major T helper cell populations, which are known to play a significant role in autoimmunity and revisited the role of the humoral autoimmune response directed against heat shock proteins (Hsps) in individuals with no history of COVID-19. While no significant differences were found in the levels of IFN-γ, IL-6, IL-22, IL-4, IL-8, IL-10, and IL-17A, between vaccinated and unvaccinated people, several positive correlations were observed between serum cytokine levels and circulating autoantibodies directed against self-Hsps exclusively in vaccinated individuals. These findings suggest that the mRNA COVID-19 vaccine does not impact cytokines involved in the pathogenesis of autoimmune diseases. Further research is required to evaluate the safety of COVID-19 vaccination in patients with autoimmune conditions, particularly those in whom anti-Hsps autoantibodies are suspected to contribute to disease development.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1549739"},"PeriodicalIF":5.7,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11949786/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.","authors":"Qianyi Zhou, Yuxin An, Xiaomei Zhang, Xia Xiao, Xue Bai, Pengjiang Liu, Yedi Pu, Juanxia Meng, Haibo Zhu, Cuicui Lyu, Huan Zhang, Yu Zhang, Tianle Xie, Haotian Meng, Hairong Lyu","doi":"10.3389/fimmu.2025.1530623","DOIUrl":"10.3389/fimmu.2025.1530623","url":null,"abstract":"<p><strong>Purpose: </strong>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.</p><p><strong>Methods: </strong>This retrospective cohort study investigated the use of tocilizumab for managing CAR-T-related CRS in 45 R/R B-ALL patients.</p><p><strong>Results: </strong>Of these, 17 patients received tocilizumab, resulting in a significant reduction in the duration of grade 3 CRS compared to those who did not receive the drug. Additionally, 10 patients showed decreased cytokine levels.Importantly, tocilizumab did not impair CAR-T cell expansion or efficacy, nor did it increase the incidence of adverse events.</p><p><strong>Conclusion: </strong>These findings suggest that tocilizumab may be an effective and safe strategy for mitigating CAR-T-related CRS in R/R B-ALL patients, potentially improving patient outcomes and survival.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1530623"},"PeriodicalIF":5.7,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11949925/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a prognostic prediction model for non-smoking lung adenocarcinoma based on pathological information and laboratory hematologic indicators: a multicenter study.","authors":"Run Xiang, Peihong Hu, Xiaoxiong Xiao, Wen Li, Xiaoqing Liao, Jun Li, Wen Zhu, Xiaoqin Liu, Qiang Li","doi":"10.3389/fimmu.2025.1566195","DOIUrl":"10.3389/fimmu.2025.1566195","url":null,"abstract":"<p><strong>Objective: </strong>To develop a simple and practical model to predict the prognostic survival of non-smoking patients with lung adenocarcinoma by combining general pathological information with laboratory hematologic indicators.</p><p><strong>Methods: </strong>Cox univariate and multivariate analyses were used to identify the variable indicators. A Cox proportional hazards model was constructed based on the selected variables to compare survival outcomes between the high-and low-risk groups of non-smoking patients with lung adenocarcinoma and to validate the model's performance. Subsequently, a nomogram model was established to systematically evaluate the impact of selected variables on prognosis.</p><p><strong>Results: </strong>Data of non-smoking patients with lung adenocarcinoma from four hospitals were retrospectively collected. We enrolled 1,172 patients, this includes 372 external validation data. Multivariate analysis identified six significant variables (<i>P</i> < 0.05): tumor TNM stage, tumor size, white blood cell count, neutrophil percentage, lymphocyte percentage, and hemoglobin level. We combined these six variables to build a model. The C-index of the training set is 0.811 (0.780-0.842), this value is 0.786 (0.737-0.835) in,test set and 0.810 (0.772-0.847) in validation set. The area under the curve (AUC) results of the predicted 3-years overall survival (OS) of the three data sets were 0.850, 0.819, and 0.860, respectively. These values for 5-years were 0.811, 0.771, and 0.849. Stratified analysis based on tumor staging showed that the model effectively distinguished outcomes (<i>P</i> < 0.0001). High-risk groups demonstrated significantly poorer prognosis compared to low-risk groups (<i>P</i> < 0.001).</p><p><strong>Conclusion: </strong>The prognostic model based on tumor TNM stage, tumor size, white blood cell count, neutrophil percentage, lymphocyte percentage, and hemoglobin levels effectively predicted the prognosis of non-smoking patients with lung adenocarcinoma. Compared with the more studied blood markers at present, the indicators of our model do not need conversion, Our model provides a useful reference for personalized diagnosis and treatment in clinical practice.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1566195"},"PeriodicalIF":5.7,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11949898/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrative miRNA-mRNA profiling uncovers mechanisms of belimumab action in systemic lupus erythematosus.","authors":"Maria Royo, Blanca Joseph-Mullol, Sebastian Sandoval, Teresa Moliné, Cristina Solé, Josefina Cortés-Hernández","doi":"10.3389/fimmu.2025.1553971","DOIUrl":"10.3389/fimmu.2025.1553971","url":null,"abstract":"<p><p>Systemic lupus erythematosus (SLE) is a complex autoimmune disorder driven by autoreactive B cells and characterized by the production of pathogenic autoantibodies. Belimumab, an anti-BAFF monoclonal antibody, has demonstrated efficacy in reducing disease activity and corticosteroid use in SLE patients, although responses remain variable. B-cell activating factor (BAFF) is essential for B cell survival and autoantibody production, positioning it as a key target in SLE pathogenesis. MicroRNAs (miRNAs), critical regulators of gene expression and immune homeostasis, have an emerging role in SLE pathophysiology. However, their regulation in response to anti-BAFF therapies, such as belimumab, remains unexplored. This study investigates miRNA-mRNA interactions in T cells, B cells, and myeloid cells from SLE patients before and after belimumab treatment. A total of 79 miRNAs associated with treatment response and 525 miRNA-gene interactions were identified. Validation in 18 SLE responders revealed significant changes in miRNA expression in T and myeloid cells, but not in B cells. Belimumab was found to modulate B cell development by regulating genes such as BLNK, BANK1, and MEF2C, as well as the CD40/CD40L axis. In T cells, miRNAs influenced interferon signaling and inflammatory cytokines via NF-κB activation. Changes in myeloid cells, characterized by the downregulation of KLF13, CCL5, and IL4, appear to be secondary to T cell modulation. These findings provide novel insights into the miRNA-mediated regulatory networks underlying belimumab's immunomodulatory effects in SLE. Further research is required to validate these findings and through <i>in vitro</i> experiments to better understand the role of miRNAs in guiding treatment responses.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1553971"},"PeriodicalIF":5.7,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11949941/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Report: CASPR2-associated autoimmune encephalitis with NF155 Antibody-positive autoimmune nodopathies: a rare case with hyponatremia onset.","authors":"Wen-Ya Wang, Jing-Ying Huang, Ying Xue, An-Ran Zhang, Ruo-Yi Guo, Zhen Jia, Ya-Fei Sun, Bin Li","doi":"10.3389/fimmu.2025.1519878","DOIUrl":"10.3389/fimmu.2025.1519878","url":null,"abstract":"<p><strong>Objectives: </strong>This case report aims to highlight the atypical presentation and management of a patient diagnosed with CASPR2-associated autoimmune encephalitis and NF155 antibody-positive autoimmune nodopathies (AN), initially presenting with limb weakness and hyponatremia.</p><p><strong>Methods: </strong>The patient was identified through clinical evaluation and diagnostic testing including serum and cerebrospinal fluid analysis, neuroimaging, and nerve conduction studies.</p><p><strong>Results: </strong>The patient exhibited limb weakness, hyponatremia, cognitive abnormalities, and peripheral nerve involvement. Diagnostic testing revealed CASPR2 and NF155 antibody are positive. Therapeutic interventions included corticosteroids, plasma exchange, and intravenous immunoglobulin therapy, followed by B-cell depletion therapy. Treatment led to improvement in walking function and normalization of antibodies.</p><p><strong>Discussion: </strong>This case report contributes to the literature by documenting a rare co-occurrence of CASPR2-associated autoimmune encephalitis and NF155 antibody-positive AN, with a unique presentation of hyponatremia. The findings underscore the importance of considering autoimmune etiologies in patients presenting with hyponatremia and neurological symptoms. Moreover, the favorable response to B-cell depletion therapy suggests a potential treatment option for similar cases. The main take away is the need for heightened clinical suspicion and comprehensive diagnostic evaluation in patients with complex neurological presentations, to facilitate timely diagnosis and appropriate management.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1519878"},"PeriodicalIF":5.7,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11949779/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combining interleukin 6 and EBV DNA levels predicts survival outcomes for patients with recurrent or metastatic nasopharyngeal carcinoma receiving chemoimmunotherapy.","authors":"Ya Liu, Zilu Huang, Chen Chen, Yujun Hu, Yalan Tao, Songran Liu, Ping Feng, Shuohan Zheng, Yunfei Xia","doi":"10.3389/fimmu.2025.1560897","DOIUrl":"10.3389/fimmu.2025.1560897","url":null,"abstract":"<p><strong>Purpose: </strong>Platinum-based chemotherapy plus PD-1 inhibitors (chemoimmunotherapy) was the standard systemic treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC). However, biomarkers to predict the survival outcomes remained unsatisfying. This study aimed to establish a simple but easily applicable model to predict the survival outcomes of R/M NPC receiving chemoimmunotherapy.</p><p><strong>Materials and methods: </strong>A total of 319 R/M NPC patients treated by chemoimmunotherapy with or without local therapy at our hospital were randomly divided into training (n=223) and validation (n=96) cohorts at a ratio of 7:3. An easily applicable prognostic risk grouping model was created using common independent predictors of progression-free survival (PFS) and overall survival (OS) in the training set. Model performance was assessed in the validation set.</p><p><strong>Results: </strong>Pretreatment IL-6 and EBV DNA levels were identified as independent prognostic factors (scored on 0-4 points), and used to develop a prognostic risk grouping model with distinct survivals: 0-1 point (low risk), 2-3 points (intermediate risk), and 4 points (high risk). In the training set, the median PFS were not reached (NR), 18.90, and 7.73 months (P<0.001) respectively in the low-, intermediate-, and high-risk groups, while the median OS were NR, NR and 13.6 months (P<0.001). Results were further confirmed in the validation set.</p><p><strong>Conclusion: </strong>This model predicted both PFS and OS in R/M NPC patients undergoing chemoimmunotherapy. This finding may help clinicians with an initial prognostic estimation but warrants further prospective investigation for the value of IL-6 and EBV DNA.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1560897"},"PeriodicalIF":5.7,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11949991/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multimodal monitoring of neutrophil activity during cardiac surgery.","authors":"Darko Jovanovski, Lisa Wohlgemuth, Pascal Max Lucien Lessing, Dominik Hüsken, Alexander Sebastian Koller, Bertram Dietrich Thomaß, Paul Müller, Marco Mannes, Sandra Nungeß, Marta Jovanovska, Bernd Mühling, Andreas Liebold, Markus Huber-Lang, David Alexander Christian Messerer","doi":"10.3389/fimmu.2025.1504944","DOIUrl":"10.3389/fimmu.2025.1504944","url":null,"abstract":"<p><p>Cardiac surgery and the associated ischemia-reperfusion injury trigger an inflammatory response, which, in turn, can contribute to organ damage, prolonged hospitalization, and mortality. Therefore, the present study performed comprehensive monitoring of neutrophil-related inflammation in patients who underwent aortic valve surgery, including extracorporeal circulation. Neutrophil-related inflammation, as well as alterations in cellular physiology, phenotype, and function, were analyzed by flow cytometry, ELISA, and microscopy. Neutrophil activation occurred intraoperatively and preceded the upregulation of conventional inflammatory markers such as C-reactive protein and interleukin-6. Perioperatively, neutrophils maintained a stable response to platelet-activating factor (PAF) with regard to CD11b and CD66b expression but showed a decreased response in CD10. Postoperatively, neutrophils exhibited marked alterations in PAF-induced depolarization, while reactive oxygen species generation and phagocytic activity remained largely stable. Surprisingly, platelet-neutrophil complex formation was severely impaired intraoperatively but returned to normal levels postoperatively. Further studies are needed to elucidate the implications of these intraoperative and postoperative changes in neutrophil and platelet activity with respect to a potential immune dysfunction that temporarily increases susceptibility to infectious or hemostatic complications.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1504944"},"PeriodicalIF":5.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11947689/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143729596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum: Pig jejunal single-cell RNA landscapes revealing breed-specific immunology differentiation at various domestication stages.","authors":"Wenyu Fu, Qinqin Xie, Pengfei Yu, Shuang Liu, Lingyao Xu, Xiaowei Ye, Wei Zhao, Qishan Wang, Yuchun Pan, Zhe Zhang, Zhen Wang","doi":"10.3389/fimmu.2025.1588642","DOIUrl":"10.3389/fimmu.2025.1588642","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/fimmu.2025.1530214.].</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1588642"},"PeriodicalIF":5.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11947721/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143729594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}